Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab

Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab

NCT01077128 ·Status: COMPLETED

Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

NCT01156532 ·Status: TERMINATED

Effect of Adalimumab Therapy on Psoriasis Patient

NCT05889338 ·Status: UNKNOWN ·Phase: NA

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00237887 ·Status: COMPLETED ·Phase: PHASE3

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs

NCT01084668 ·Status: COMPLETED

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689 ·Status: COMPLETED ·Phase: PHASE3

Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea

NCT03925441 ·Status: COMPLETED

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00338754 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities

NCT01401452 ·Status: COMPLETED

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

NCT01646073 ·Status: COMPLETED ·Phase: PHASE3

Adalimumab in Adult Japanese Subjects With Psoriasis

NCT00647400 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Psoriatic Inflammation Markers Predictive of Response to Adalimumab

NCT03389984 ·Status: COMPLETED ·Phase: NA

Adalimumab Biosimilar in Clinical Practice

NCT04808739 ·Status: COMPLETED

Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

NCT07190391 ·Status: NOT_YET_RECRUITING

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

NCT00513370 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

NCT02016482 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

NCT01202565 ·Status: COMPLETED

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645892 ·Status: COMPLETED ·Phase: PHASE2

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00645905 ·Status: COMPLETED ·Phase: PHASE2

A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece

NCT02713295 ·Status: COMPLETED

Post Marketing Observational Study on Venezuelan Patients With Psoriasis

NCT01758705 ·Status: WITHDRAWN

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

NCT01265823 ·Status: COMPLETED ·Phase: PHASE4

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

NCT01076192 ·Status: COMPLETED

The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

NCT01088165 ·Status: UNKNOWN ·Phase: PHASE4